Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Real-World Characteristics and Survival Outcomes of Patients with Mantle Cell Lymphoma Treated with Covalent Bruton's Tyrosine Kinase Inhibitors in First-Line

Ahmed Sawas, Niquelle Brown Wadé, James Roose

Blood (2024) 144 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2024-203687

Published: 2024

Journal Articles

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Mark N Sorial, Sean M McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. J. Fernandez Turizo, Caroline MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra W Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven Horwitz, Mwanasha H. Merrill, Eric D. Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie G Ford, Martina Manni, Monica Civallero, Tetiana Skrypets, Massimo Federico, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2024) 144 (Supplement 1): 465.

https://doi.org/10.1182/blood-2024-201874

Published: 2024

Journal Articles

A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Elif Yilmaz, Xiaoliang (Wendy) Wang, Niquelle Brown Wadé, Yu-Lun Liu, Praveen Ramakrishnan Geethakumari, Ahmed Sawas

Blood (2024) 144 (Supplement 1): 3719.

https://doi.org/10.1182/blood-2024-206358

Published: 2024

Journal Articles

Methods for Identification of Blood Product Transfusions in a Cohort of Myelofibrosis Patients: An Assessment of Data Capture Using Insurance Claims and Electronic Health Record Abstraction

Anthony Proli, Ahmed Sawas, Gene Ho, Jingru Wang, Christina Fullerton

Blood (2023) 142 (Supplement 1): 7292.

https://doi.org/10.1182/blood-2023-189374

Published: 2023

Journal Articles

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Blood (2023) 142 (Supplement 1): 990.

https://doi.org/10.1182/blood-2023-177823

Published: 2023

Journal Articles

Low Socioeconomic Status Confers Poorer Real-World Overall Survival for Patients with Acute Myeloid Leukemia Treated in the Modern Era

Mark A Guinter, Brendan T Kerr, Gregory S Calip, Anita J Kumar, Ahmed Sawas

Blood (2023) 142 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2023-186137

Published: 2023

Journal Articles

Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder

Maegan Ford, Evelyn Orlando, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 3794–3795.

https://doi.org/10.1182/blood-2022-163813

Published: 2022

Journal Articles

Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder

Maegan Ford, Evelyn Orlando, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 3777–3778.

https://doi.org/10.1182/blood-2022-160147

Published: 2022

Journal Articles

Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma

James Roose, Yichen Lu, Amy E Pierre, Ahmed Sawas, Gregory S Calip

Blood (2022) 140 (Supplement 1): 13191–13193.

https://doi.org/10.1182/blood-2022-159044

Published: 2022

Journal Articles

The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation

Evelyn Orlando, Maegan Ford, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 12085–12086.

https://doi.org/10.1182/blood-2022-158050

Published: 2022

Journal Articles

Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV + ) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study

Vikas Dharnidharka, Dhanalakshmi Thirumalai, Ulrich Jaeger, Weizhi Zhao, Daan Dierickx, Pengcheng Xun, Periana Minga, Ahmed Sawas, Natalia Sadetsky, Paul Chauvet, Erin Sundaram, Arie Barlev, Heiner Zimmermann, Ralf Ulrich Trappe

Blood (2021) 138 (Supplement 1): 2528.

https://doi.org/10.1182/blood-2021-147307

Published: 2021

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2448.

https://doi.org/10.1182/blood-2021-154490

Published: 2021

Journal Articles

Feasibility of Capturing AML Morphologic Response Assessments Using Real-World Data

Mark Guinter, Hankyul Kim, Alexandra Jacob, Hannah Wise, Kyusun Cha, Ahmed Sawas

Blood (2021) 138 (Supplement 1): 4377.

https://doi.org/10.1182/blood-2021-147291

Published: 2021

Journal Articles

Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial

Stefka Tyanova, Tao Xu, Mellissa Williamson, Alberto Rocci, Wan-Jen Hong, Huan Jin, Sudeep Karve, James Roose, Ahmed Sawas, Shaji Kumar

Blood (2021) 138 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2021-147713

Published: 2021

Journal Articles

Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Pei-Hsuan Chen, Mikel Lipschitz, M.S., Scott Rodig, MD PhD, George Vlad

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140096

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Ahmed Sawas, MD, Constance Lau, MPH, Michael Thomson, MS, Kathleen Maignan, NP, MSN

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141274

Published: 2020

Journal Articles

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Francesca Montanari, MD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Jennifer Kimberly Lue, MD, Enrica Marchi, MD, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 2909.

https://doi.org/10.1182/blood-2019-131841

Published: 2019

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Blood (2019) 134 (17): 1395–1405.

https://doi.org/10.1182/blood.2019001285

Published: 2019

Includes: Supplemental data

NARROW

Real-World Characteristics and Survival Outcomes of Patients with Mantle Cell Lymphoma Treated with Covalent Bruton's Tyrosine Kinase Inhibitors in First-Line

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Methods for Identification of Blood Product Transfusions in a Cohort of Myelofibrosis Patients: An Assessment of Data Capture Using Insurance Claims and Electronic Health Record Abstraction

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Low Socioeconomic Status Confers Poorer Real-World Overall Survival for Patients with Acute Myeloid Leukemia Treated in the Modern Era

Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder

Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder

Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma

The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation

Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV + ) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Feasibility of Capturing AML Morphologic Response Assessments Using Real-World Data

Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial

Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only